Silence Therapeutics
Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.
Top Stages
2 past transactions
Arrowhead Pharmaceuticals
Post in 2017
Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California, focused on developing innovative medicines for the treatment of intractable diseases, particularly those with a genetic origin characterized by the overproduction of specific proteins. The company's diverse pipeline includes RNA interference (RNAi) therapeutics such as ARO-AAT for liver diseases associated with alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, and ARO-HIF2 for clear cell renal cell carcinoma, among others. Arrowhead is also exploring treatments for various conditions, including chronic hepatitis B virus infection and cardiovascular diseases. The company collaborates with prominent pharmaceutical firms, including Janssen Pharmaceuticals and Takeda Pharmaceuticals, to develop additional RNAi therapeutic candidates. Originally founded as Arrowhead Research Corporation in 1989, it adopted its current name in April 2016.
Intradigm
Acquisition in 2009
Intradigm is a private biotechnology company specializing in the development of systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, particularly in the field of oncology. The company leverages its expertise in drug development and delivery to create an innovative RNAi platform. Central to its approach is the proprietary RNAi Nanoplex delivery technology, which allows for the targeted systemic delivery of RNAi therapeutics to specific tissues. Intradigm's portfolio includes a range of siRNA sequences designed to address various oncology and other disease targets, complemented by biodegradable polycationic polymers that enhance the delivery of these therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.